LUXTURNA

This brand name is authorized in Austria, Brazil, Croatia, Estonia, France, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug LUXTURNA contains one active pharmaceutical ingredient (API):

1	Voretigene neparvovec UNII 2SPI046IKD - VORETIGENE NEPARVOVEC
	Voretigene neparvovec results to transduction of retinal pigment epithelial cells with a cDNA encoding normal human RPE65 protein (gene augmentation therapy), providing the potential to restore the visual cycle in patients with vision loss due to inherited retinal dystrophy.
	Read more about Voretigene neparvovec

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LUXTURNA Concentrate and solvent for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01XA27		S Sensory organs → S01 Ophthalmologicals → S01X Other ophthalmologicals → S01XA Other ophthalmologicals
Discover more medicines within S01XA27

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	526520120098907
EE	Ravimiamet	1783649
ES	Centro de información online de medicamentos de la AEMPS	1181331001
FR	Base de données publique des médicaments	69302990
GB	Medicines & Healthcare Products Regulatory Agency	379821
IL	מִשְׂרַד הַבְּרִיאוּת	8480
IT	Agenzia del Farmaco	047423013
LT	Valstybinė vaistų kontrolės tarnyba	1086767
NL	Z-Index G-Standaard, PRK	199362
PL	Rejestru Produktów Leczniczych	100416513
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68641001